A major investor wants Bristol-Myers to “expand its [immunotherapy] portfolio as much as possible,” potentially through a merger with another drugmaker, an unnamed source told Bloomberg.
Analysts identified Pfizer, Novartis and Gilead Sciences as potential candidates to takeover the drugmaker.
Despite talk of a deal, Bristol-Myers is urging investors to wait for new trial results and scientific data on a myriad of combination therapies — some of which combine Opdivo with other drugs, according to the report.
A breakthrough combination therapy would expand the market for Opdivo, which represents nearly 20 percent of Bristol-Myers’ $19.4 billion in annual revenue, reports Bloomberg.
More articles on supply chain:
7 drugmakers in the headlines
4 ways hospitals can lower inpatient drug costs
6 must-reads for supply chain leaders this week
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
